BTIG Maintains Buy on RxSight, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on RxSight (NASDAQ:RXST) and raises the price target from $25 to $29.
June 05, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman maintains a Buy rating on RxSight and raises the price target from $25 to $29.
The raised price target by BTIG analyst Ryan Zimmerman indicates a positive outlook for RxSight's stock. This news is likely to increase investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100